Concepedia

Author

Mary Motyl

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

M Motyl, M R Motyl, M. Motyl, M. R. Motyl, Mary Motyl, Mary R Motyl, Mary R. Motyl, Robert Badal

184

Publications

6.5K

Citations

42

H-Index

78

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)University of ManitobaUnited States Military AcademyMSD (Spain)University of Pretoria
MM

About

Mary Motyl is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, microbiology, and antimicrobial resistance.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

31

48

3.8K

2

Health Sciences

16

19

1K

3

Natural Sciences

3

3

103

4

Engineering

2

2

412

5

Public Health

1

1

52

Mary Motyl

×

88

Publications

5.6K

Citations

41

H-Index

YearCitations

Platensimycin is a selective FabF inhibitor with potent antibiotic properties

Jun Wang, S.M. Soisson, Katherine Young,

Nature

2006

809

Discovery of platencin, a dual FabF and FabH inhibitor with <i>in vivo</i> antibiotic properties

Jun Wang, Srinivas Kodali, Sang Ho Lee,

Proceedings of the National Academy of Sciences

2007

380

Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

Johan Maertens, Galia Rahav, Dong‐Gun Lee,

The Lancet

2021

257

Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against <i>Candida</i> and <i>Aspergillus</i> Species

Frank C. Odds, Mary Motyl, Roberto Andrade,

Journal of Clinical Microbiology

2004

173

Genomic Epidemiology of Global Carbapenemase-Producing<i>Enterobacter</i>spp., 2008–2014

Gisele Peirano, Yasufumi Matsumura, Mark D. Adams,

Emerging infectious diseases

2018

148

Wild-Type MIC Distribution and Epidemiological Cutoff Values for <i>Aspergillus fumigatus</i> and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods

Michael A. Pfaller, Daniel J. Diekema, Mahmoud A. Ghannoum,

Journal of Clinical Microbiology

2009

139

Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome

Nicholas A. Kartsonis, John Killar, Lori Mixson,

Antimicrobial Agents and Chemotherapy

2005

138

<i>In Vitro</i> Activity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria

Elizabeth B. Hirsch, Kimberly R. Ledesma, Kai-Tai Chang,

Antimicrobial Agents and Chemotherapy

2012

138

<i>In Vitro</i> Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)

Sibylle Lob, Meredith Hackel, Krystyna M. Kazmierczak,

Antimicrobial Agents and Chemotherapy

2017

136

Global Distribution and Outcomes for Candida Species Causing Invasive Candidiasis: Results from an International Randomized Double-Blind Study of Caspofungin Versus Amphotericin B for the Treatment of Invasive Candidiasis

Arnaldo Lopes Colombo, John R. Perfect, Mark J. DiNubile,

European Journal of Clinical Microbiology & Infectious Diseases

2003

127

Page 1